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Objective: To compare the short- and long-term outcome and the costs involved in balloon angioplasty (BA) and thrombo- 
endarterectomy (EA) of short femoropopliteal occlusions. 
Design: Retrospective study. 
Patients and methods: Forty-one lower limbs underwent EA from 1980 until 1988 and BA was performed in 62 limbs 
between 1988 and 1993. The two groups of patients were well matched for age, gender, cardiovascular risk-factors and the 
length of the femoropopliteal occlusions. In addition to clinical follow-up colour-Duplex scanning and intraarterial DSA 
were performed. Complete occlusions or significant restenoses were considered failure of the reconstruction. Actual costs 
were calculated by the hospital economic administration. 
Results: The 3-year primary patency in EA patients was 87% and in the BA group 44% (p = 0.0002). Redo procedures 
were required in seven (17%) patients with EA and in 24 (39%) with BA. Patency after redo procedures, i.e. tertiary 
patency, was 94% and 74% after 3 years in the EA and BA group respectively (p = 0.14). The mean cost of the primary 
treatment was higher in EA than in BA patients (p < 0.001). Mean total treatment costs including the expenses involved 
with redo procedures were also higher in the group with EA than with BA (p < 0.001). However, the cost-effectiveness 
expressed as the total costs per month tertiary patency, was not significantly different for the two treatment groups; in 
patients with EA the ratio of total treatment costs and tertiary patency was NF1 309, and in patients with BA NFI 
287. 
Conclusion: Contrary to the general view the expenses associated with surgical treatment are comparable with those of an 
endovascular procedure, if the costs are expressed as a cost-to-patency ratio. 
Key Words: Cost-effectiveness; Balloon angioplasty; Thrombo-endarterectomy. 
Introduction 
Balloon angioplasty (BA) is a relatively minor proce- 
dure for treating peripheral arterial disease causing 
intermittent daudieation and is used on a large and 
increasing scale. While the overall 3-year patency of 
BA for disease in the superficial femoral artery is 
reported around 62%, the durability of patency is less 
impressive (approximately 40%) if complete occlu- 
sions are involved. 1-~ Patients with occlusions of the 
entire superficial femoral artery (SFA) are usually 
beyond treatment by endovascular procedures and 
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often require bypass urgery, particularly if they suffer 
from critical ischaemia. Short occlusions, if associated 
with disabling claudication, may be considered an 
appropriate indication for treatment by endovascular 
recanalisation and dilatation. 5 
Before the rapid growth of balloon angioplasty, 
thrombo-endarterectomy (EA) had long been the 
method of choice in the treatment of segmental 
occlusive disease of the superficial femoral artery in 
several institutions. 6-9 EA involves shorter operating 
time than autologous vein bypass grafting, while the 
saphenous vein is saved for future use. In addition the 
high costs and risk of infection associated with a 
prosthetic femoropopliteal bypass are avoided. Five- 
year patency rates of 66-71% are reported and the 
incidence of secondary procedures i lOW. 7-9 
In our institution we continued to use EA for short 
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SFA occlusions until 1988, after which BA was used. 
Suggestions in the literature of lower costs associated 
with endovascular techniques were an important 
consideration for this change of treatment policy, z° 
However, assumptions of this kind should be viewed 
with caution as the initial cost savings of BA might be 
offset by the late costs incurred by the need for redo 
procedures. In this analysis the actual costs of in- and 
out of hospital investigations, treatment, follow-up by 
clinical and noninvasive xaminations, and expenses 
for revisional and redo procedures were assessed and 
correlated with the duration of the arterial patency in 
two groups of patients, one with EA and the other 
with BA. Factors that influence specific cost aspects 
were identified. 
Patients and Methods 
Patient population, treatment and follow-up 
Thirty nine patients undergoing 41 EA procedures 
were admitted to our hospital between 1980 and 1988. 
Clinical data on this group were collected retro- 
spectively. Together with physical examination, preop- 
erative ankle-brachial blood pressure-index (ABI) 
assessment and diagnostic arteriography were per- 
formed. Criteria for inclusion to the study population 
were complete occlusions of the femoropopliteal 
artery with a maximum length of 15 cm. Two 
techniques were used to accomplish the endarter- 
ectomy. An open technique with a single longitudinal 
arteriotomy was performed in 34 (83%) and a semi- 
closed technique with two longitudinal arteriotomies 
and a Volmar stripper in seven patients (17%). All 
arteriotomies were closed by a patch, vein in 15 (37%) 
and polytetrafluoroethylene (PTFE) in 26 patients 
(63%). Operative techniques were comprehensively 
described elsewhere. 6# Postoperative oral anticoagu- 
lation was prescribed for all patients indefinitely. 
Regular follow-up included ABI determinations and 
in patients operated on after 1986 an annual colour- 
Duplex examination was performed uring the first 3 
years. In addition a colour-Duplex examination or an 
intraarterial digital subtraction angiography (IA DSA) 
was obtained in the patients with open femor- 
opopliteal systems who were still visiting our out- 
patient clinics between 1992 and 1994. 
Balloon angioplasty was the treatment from 
1988--1993 in 62 patients with a complete occlusion 
(maximum length 15 cm) of the SFA or above-knee 
popliteal artery. All relevant clinical data of this 
patient group were recorded prospectively. For recan- 
alisation a hydrophylic glidewire, a high frequency 
hottip catheter or a Rotacs-catheter was used, and the 
occlusion dilated with a slightly oversized angioplasty 
balloon (Cordis ®, 5--6 French in diameter). Procedures 
were performed either percutaneously in the angiog- 
raphy suite in 42 patients (68%) or via a cut-down 
approach in the operating room in 20 patients (32%). A 
technically failed BA was, depending on the cause of 
failure and arteriographic findings, either treated 
conservatively or by an early endarterectomy. Aspirin 
80 mg was started before the procedure and continued 
after discharge indefinitely. Follow-up visits included 
ABI assessment and a colour-Duplex surveillance 
schedule consisting of three studies during the 1st 
year, two studies during the 2nd year and one study 
during the 3rd year. 
The study of two groups treated in different ime 
periods resulted in differences in follow-up. Because 
one of our objectives was to compare costs in relation 
to the duration of patency, we had to adjust for the 
considerably onger patency periods in the EA group. 
This mathematical djustment was performed by 
cutting off follow-up periods at 6 years and randomly 
assigning a shorter follow-up term to patients oper- 
ated on in the early 1980s. This adjustment resulted in 
a median follow-up of 27 months (range 7-72) in the 
EA group and 23 months (range 0--69) in BA patients. 
In addition the duration of follow-up profile, i.e. the 
frequency distribution of different follow-up terms 
became comparable. This adjustment of follow-up 
periods in the two groups allowed a meaningful 
comparison of costs related to patency periods. 
Cost data 
Hospital and physician costs for treatment and follow- 
up of the selected patient category were identified 
retrospectively b careful examination of one quarter 
of the patient records. All information involved with 
catering, hotel costs, consumable items such as dress- 
ings and syringes, pharmacy and labour time spent by 
medical and paramedical staff was retrieved and the 
mean values were entered into a cost-calculation 
model. Cost centres were the outpatient dinic, hospi- 
tal ward, angiography suite, operating room and 
vascular laborator3a For organisation of the data we 
defined "standard cost periods", each containing 
several components that influenced costs (Table 1). 
The records of any individual patient were subse- 
quently reviewed and the appropriate set of standard 
cost periods was determinated onthe basis of the type 
of initial procedure, length of stay from the date of 
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Table 1. Standard cost periods and components 
Mean costs per patient (NFI) 
Standard cost period EA BA 
1. Preprocedural investigations 814 692 
Vasc. surg. consultation, vasc. laborator)5 IA DSA, internal medicine or cardiology consultation I, 
biochem. / haematol.lab., ECG 
2: Primary hospital admission 
duration of stay (d), ICU1% physiotherapy 1, biochem./haematol.lab., ECG, pharmacy 
3. Operating room/angiography suite 
1 1 fee vascular surgeon, fee anaesthesiologist, fee radiologist a,use of operating room/recovery 
room s, use of angiograpby suite 2, labour time of staff:~, prosthetic materials1§, sterile and non- 
1 1 sterile consumable items, bloodbank, LV. fluids, pharmacy 
4. Postprocedural follow-up 
1st year 455 912 
4 visits outpatient clinic, fee vascular surgeon, 1-3 Duplex exam., specialist fee for duplex, 
anticoagulants 1, aspirin 2
2nd year 406 594 
2 visits outpatient clinic, fee vascular surgeon, 1-2 Duplex exam**, specialist fee for Duplex, 
anticoagulants 1, Aspirin 2 
3rd yeartt 382 382 
i visit outpatient clinic, fee vascular surgeon, 1Duplex exam, specialist fee for Duplex, 
anticoagulants 1, Aspirin 2 
5. Secondary and tertiary procedures 
Early redo operation - -  4063 
2 2 2 operating room/recovery room, labour of staff a, bloodbank, LV. fluids, prosthetic 
2 2 2 2 2 materials, consumable items, fee vasc. surg. and anaesthesiol., ICU, pharmacy 
Late bypass~::~ 
IA DSA, labour of staff, bloodbank, I.V. fluids, prosthetic materials, fee vasc. surg. and 
anaesthesiol., consumable items, ICU, pharmacy, biochem./haematol, lab, ECG, 
physiotherapy, secondary admission days 
Late PTA:~:~ 
IA DSA, angiography suite, labour of staff, catheters, fee for radiologist, consumable items, 
pharmacy 
1310 + d* x 236 143 + d x 236 
2896 1773 
8886 + d x 236 8886 + d x 236 
2165 + d x 236 2165 + d x 236 
EA, endarterectomy; BA,balloon angioplasty. 
1 Component inEA only. 2 Component inBA only. 
* d: length of stay (days) times the cost of one admission day. 
t ICU admission was for i day in 60% of EA patients. 
1: Labour time of OR staff or EA 2.5 h, for angiography suite staff 1.5 h, for radiologist I h. 
§ PTFE patch was used in 63% of operations and vein patch in the remainder. 
** Duplex exams after EA were: one every ear in the first 3 years. After BA: three in the first year, two in the second year and one in the third 
year. 
tt After the third year only fysical examinations and ankle blood pressure measurements were done. 
~ A discount rate of 5% was used for any additional year after the primary procedure. 
admission to the date of discharge, associated proce- 
dures, complications, occurrence of an early reinter- 
vention because of in-hospital failure, number  of years 
fol low-up, number  and type of late reinterventions 
and durat ion of the involved readmissions. Length of 
stay (days) and number  of fo l low-up years were 
entered as numerical  variables in the patient's pecific 
data set. In this model  a simplif ication was used with 
regard to preoperat ive arteriographic examination. In 
practice a wide var iety of schemes were used, depend-  
ing on the concepts of clinical management  at the 
different imes dur ing the per iod in which the patients 
of this s tudy were treated. Seldinger catheterisation 
with conventional  arter iography and IA DSA had 
been used either at separate admissions, or dur ing the 
same admission as that used for the treatment, with an 
interval of some days. In the cost-calculation model  
for all cases an outpatient IA DSA was al lowed for as 
is our current practice. Some other estimates with 
regard to the use of the ICU and of prosthetic 
materials based on the retrospective chart s tudy are 
represented in the footnotes to Table 1. In the cost- 
effectiveness calculation actual costs are to be pre- 
ferred over charges, i.e. hospital returns, n In this 
s tudy actual cost calculation of all identif ied compo-  
nents of the different cost per iods was per formed by  
one of the authors (C.N.) using the Cost Centre 
Method as described by  Bogaert in 1985.12 Actual costs 
contained direct costs and indirect costs. Direct costs 
were constituted by  labour time and wage data of 
medical  residents, paramedical  and nurs ing staff in 
addit ion to costs of sterile and non-steri le consumable 
items and specialist fees. Indirect costs inc luded 
overhead, write-off and interest costs of facilities and 
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equipment. Methods for estimating actual costs of 
physician services are lacking and therefore this 
component is represented by the fees charged to the 
insurance companies. It was felt that charges consti- 
tuted a reasonable approach of the specialist services. 
Because of the wide difference in frequency of 
procedures in the overall 13 year study period, with 
EA only used in the first 8 years and BA in the second 
period, unadjusted cost figures would not give a 
current reflection of financial demands of the different 
patient groups. To make statistical analysis mean- 
ingful, all cost data for staff, consumables and over- 
heads were recalculated to actual 1992 prices in Dutch 
guilders. 
Definitions and data analyses 
All prospectively collected clinical information was 
recorded on coded data sheets and subsequently 
entered into a computerised database and combined 
with the financial data. Mean costs per patient of the 
primary treatment (standard cost periods 1-3) and the 
total treatment (standard cost periods 1-5) were 
calculated for groups: with EA, for the overall BA 
group, for patients with BA without early failure and 
with early clinical failure. A discount rate of 5% per 
year was used throughout he analysis for costs of 
secondary and tertiary procedures and admission. 13 
For comparison of cost data the Mann-Whitney test 
was performed. 
Several endpoints of improvement by the proce- 
dures were assessed. In all patients with BA and in 24 
of patients (59%) with EA, patency of the recon- 
structed femoropopliteal segment was assessed either 
by colour-Duplex or by IA DSA. The ratio between the 
peak systolic velocity (PSV) at the treated segment and 
a normal SFA segment was used to investigate the 
development of restenosis. A PSV ratio > 3.0 was 
considered failure of treatment. We elected this ratio 
for the study because of its reported value in predict- 
ing the progression of stenoses to complete arterial 
14 occlusion. Primary patency determined by life-table 
analysis ended if a PSV ratio > 3.0 was observed or if 
a restenosis > 70% diameter eduction or a reocclu- 
sion was demonstrated. In patients with EA without 
colour Duplex or IA DSA at follow-up, a drop in ABI 
> 0.10, absence of previously palpable distal pulses 
and return of clinical symptoms was considered an 
indication of a failure. In the life-table analysis there 
was censuring of patients who were lost to follow-up 
discharged or died. Secondary patency was not 
considered as there was only one thrombectomy in
this series, which was classified for the life table 
analysis as a redo procedure. The effect of redo 
procedures, either by endovascular o by open surgery 
was assessed and defined as "tertiary patency'. In 
addition, the clinical/haemodynamic patency was 
assessed, using the Society for Vascular Surgery and 
the International Society for Cardiovascular Surgery5 
(SVS/ISCVS) scale of post-procedural improvement. 
This scale ranges from -3 for severe worsening to + 3 
for normalisation of ABI and disappearance of symp- 
toms. All patency rates were assessed by the Kaplan 
Meier life-table method. Group comparisons of 
patency rates were performed by log-rank tests. 
Cost-effectiveness was determinated by assessing 
the costs per month patency in the patient groups with 
EA and BA. Therefore the ratio between the amount of 
costs and the corresponding number of months 
patency in each of the study groups was calculated. 
The cost per month for primary patency was the costs 
of standard cost period 1-3 divided by the duration of 
primary patency. The cost per month for tertiary 
patency was represented by costs of standard cost 
period 1-5 divided by the tertiary patency period. 
Generallj6 a better cost-effectiveness is represented by 
a lower ratio. The primary patency period in patients 
with an early (in-hospital) or technical failure was for 
the purpose of this analysis considered to equal 1 
month. To determine the robustness of outcome of the 
cost-effectiveness a essment we performed a sensitiv- 
ity analysis by changing the most relevant variables 
and comparing the recalculated results for the two 
t reatment groups. 16 
The relationship of the hospital length of stay (LOS) 
as an important cost determining factor and different 
clinical variables was studied by log-rank testing and 
subsequently by a multivariate analysis. 17 Therefore 
the LOS was considered the duration to the event, 
which was discharge from the hospital. ~8 The varia- 
bles that were tested for independent influence were: 
the type of treatment, nicotine use, age of the patient, 
length of occlusion, poor runoff, occurrence of compli- 
cations or technical failure of treatment and associated 
operative procedures. 
Results 
Study groups 
The EA and BA groups had a comparable composition 
with regard to most clinical characteristics and risk 
factors of peripheral arterial occlusive disease (Table 
2). The average age of EA patients was 61 years (range 
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Table 2. Patient demographics, risk factors, clinical and arterio- 
graphic characteristics in groups treated with EA and BA 
Treatment group 
Table 3. Complications and associated procedures in groups with 
EA and BA 
Variable No. with EA (%) No. with BA (%) Variable 
Sex 
Male 27 (69) 45 (73) 
Female 12" (31) 17 (27) 
Presenting symptoms 
Moderate claudication 18 (44) 50 (80) 
Severe claudication 17 (41) 11 (18) 
Restpain or necrosis 6 (15) 1 (2) 
Associated diseases and risk 
factors 
Diabetes mellitus 11 (27) 16 (26) 
Hypertension 6 (15) 5 (8) 
History of smoking 36 (88) 45 (73) 
Hyperlipaemia 1 (2) 1 (2) 
Coronary heart disease 2 (5) 9 (15) 
Localization ofocclusion 
Proximal SFA 1 (2) 1 (2) 
Distal SFA 40 (98) 56 (90) 
Above-knee popliteal rtery --  (--) 5 (8) 
Runoff status 
2--3 vessels 39 (95) 48 (77) 
0-1 vessel 2 (5) 14 (23) 
EA, endarterectomy; BA, balloon angioplasty. 
* Two patients had both legs treated by EA. 
33-78) and of BA patients 64 years (range 47-78). The 
length of the treated lesions was almost similar in the 
EA group (median 6 cm, range 1-15) and the BA 
category (median 5 cm, range 0.5-15). Presenting 
symptoms appeared more severe in the group with 
EA. In addition, the crural runoff appeared somewhat 
different with more patients presenting with 0-1 
vessel runoff in the BA group. Moreover, the BA group 
contained five patients with popliteal occlusions com- 
pared to none in the EA group. Following treatment, 
the BA group were only given aspirin whereas the EA 
group were anticoagulated. 
Treatment group 
No. with EA (%) No. with BA (%) 
Complication 
Early ocdusion 1 (2) 5 (8)* 
Failed recanalisation -- 4 (6)* 
Haematoma 1 (2) 2 (3) 
Wound infection 1 (2) -- 
Pulmonary/cardiac 2 (5) -- 
Associated procedure 
Non related~ 8 (20) 6 (10) 
Relatedt 4 (10) 8 (13) 
EA, endarterectomy; BA, balloon angioplasty. 
* Early occlusion and failed recanalisation constitute pmnary failures. 
The causes were major dissections and perforations. Minor 
dissections with a residual stenosis < 30% were not considered 
complications. 
t Related associated procedures are patchplasties of the ipsilateral 
common or deep femoral artery. Non-related associated procedures 
are all other simultaneous treatments. 
improvement, after the primary procedure in which a 
post-procedure classification of < + 1 was the qualify- 
ing event was 89% (S.E. 5%) after 3 years in the EA 
group and 46% (S.E. 9%) in BA patients. The primary 
anatomical patency presented comparable figures; it 
was higher in EA patients, 87% (S.E. 6%), compared to 
44% (S.E. 9%) in BA patients after 3 years (Fig. 1). If 
only BA patients with initial success are considered, 
the 3-year pr imary patency was 53% (S.E. 10%), which 
is still lower than in the EA group. Secondary 
procedures to maintain a patent femoropophteal 
artery were required in seven EA patients and in as 
many as 24 of BA patients (Fig. 2). The tertiary 3-year 
patency resulting from these redo procedures was 
comparable for EA and BA groups, 94% (S.E. 4%) and 
74% (S.E. 8%) respectively (Fig. 3). Initial successful 
BA had an almost similar tertiary patency than the 
overall BA category, 76% (S.E. 9%) at 3 years. 
Complications, econdary procedures and follow-up 
results 
Complications and associated procedures are repre- 
sented in Table 3. The most frequent complication was 
early occlusion or failed recanalization i nine (15%) 
patients with BA. Associated procedures included 
sympathectom~ forefoot amputation, simultaneous 
bifurcation prosthesis in EA patients and ipsilateral or 
contralateral patchplasties in the common femoral or 
deep femoral artery in BA patients. The prevalence of 
associated procedures is comparable in the two 
treatment groups. 
The maintenance of clinical / haemodynamic 
Costs in treatment groups and cost-effectiveness 
The mean costs involved in the initial investigation, 
admission and treatment, i.e. primary treatment costs 
(standard cost periods 1-3), in EA patients are 
significantly higher than the costs in BA patients. BA 
with initial success was associated with the lowest 
costs, while initial BA failure resulted in considerably 
higher expenses than EA, caused by the costs of two 
procedures and a prolonged admission (Fig. 4). If total 
treatment costs are considered, in which the costs of 
redo procedures and follow-up are included (standard 
cost period 1-5), endarterectomy still is more expen- 
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sive than BA, although the difference is smaller than in 
the primary treatment costs. Apparently the secon- 
dary treatment costs in BA do partly offset the initial 
cost advantage of the endovascular p ocedures. 
The cost-effectiveness of arterial reconstructions 
expressed as the ratio between costs and the appro- 
priate number of months patency are illustrated in Fig. 
5. The costs per month primary patency in EA patients 
are comparable to the overall BA group. In this 
comparison BA with initial failure compares quite 
unfavourably with all other treatment categories. If
the costs in relation to the tertiary patency period are 
calculated, it is apparent that the advantage of low 
primary treatment costs of BA is negated by the higher 
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Fig. 1. Cumulative primary patency rates (Kaplan-Meier curves) in patients who underwent endarterectomy (EA), patients with balloon 
angioplasty (BA) with initial success and all patients with balloon angioplasty (including early failures). Numbers at risk represent patients 
at risk at indicated time points.lp = 0.0024, 2p = 0.0064. 
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endarterectomy (EA) and balloon angioplasty (BA). 
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Fig. 4. Mean costs of primary treatment (standard cost periods 1-3) and costs of total treatment including redo procedures and follow-up 
(standard cost periods 1-5). CA, endarterectomy; BA, balloon angioplasty: Small characters correspond to the statistical comparison of 
a b c categories: p=0.0000, p=0.0000, p=0.0000, d p=0.0000, e p=0.04, f p=0.0006. (R) cost of primary treatment; ([]) cost of total 
treatment. 
Cur J Vasc Endovasc Surg Vol 10, July 1995 
Treatment of Short Occlusive Lesions in the Femoropopliteal Artery 47 
costs of redo procedures resulting in comparable costs 
per month tertiary patency in the two treatment 
groups. 
Sensitivity analysis 
A sensitivity analysis was performed with regard to 
the costs per month tertiary patency. Relevant factors 
that were varied were the number of admission days 
(days in standard cost periods 2 and 5, Table 1) and the 
costs involved with the procedures (procedural cost 
figures in standard cost periods 3 and 5, Table 1). The 
effects of an increase and a decrease of 30% of both 
factors were investigated. The greatest effect was 
observed by changes in procedural costs in BA 
patients (Table 4). However, none of these variations 
influenced the relation of the cost-to-tertiary patency 
ratio between the groups with EA and BA sig- 
nificantly (p = 0.2 to 0.4). This observation supports the 
conclusion that there is no difference in cost-effective- 
ness between the two treatment methods. 
Risk factors for prolonged uration of stay 
The costs for admission at surgical ward, i.e. routine 
room, catering, pharmac)~ laboratory and infusions 
constitute approximately 32% of the total costs in the 
overall study population, 41% in the EA group and 
197o in patients with BA. To rule out any simultaneous 
influences we performed a multiple regression analy- 
sis of factors that might correlate with the duration of 
admission. The LOS for secondary admissions was 
considered an extension of the initial admission for 
this analysis. Three factors demonstrated an inde- 
pendent influence on the LOS: EA being the treatment 
method (relative risk 6.8, p < 0.001), the occurrence of 
complications or early failure during admission (rela- 
tive risk 2.9, p < 0.001) and whether associated 
procedures were performed (relative risk 2.9, p < 
0.001). 
Discussion 
In the Dutch financial health care system charges of 
hospitals and physicians were completely reimbursed 
by compulsory and private health care insurance 
systems until governmental legislation halted this 
open-end system in 1981. From that year a fairly rigid 
budget system was introduced to constrain hospital 
charges. Exceeding the assigned budget 1 year 
requires that a hospital has to compensate its negative 
budget result in the years thereafter, while any 
underexpenditure of the budget can be used autono- 
mously at a later time. The charges of Dutch medical 
specialists, of whom the majority work on a fee-for- 
service basis, does not fall under the budget system. 
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success failure 
Fig. 5. Cost-to-patency ratios: primary treatment cost per month primary patency and total treatment cost per month tertiary patency. EA, 
a b endarterectomy; BA, balloon angioplasty. Small characters correspond tO the statistical comparison of categories: p =N.S., p = 0.06, 
c d e f p = N.S., p = N.S., p = 0.0000, p = 0.01. (11) cost per month for primary patency; ([3) cost per month for tertiary patency. 
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Table 4. Costs per month tertiary patency for different duration of 
admission and procedural costs 
Costs in NF1 per month 
tertiary patency 
EA patients 13A patients 
Duration of admission 
30% less than observed 280 269 
Observed 309 287 
30% greater than observed 343 309 
Procedural costs 
30% less than observed 278 241 
Observed 309 287 
30% greater than observed 344 330 
EA, endarterectomy; BA, balloon angioplasty. 
However, specialists automatically feel the constraints 
of their hospital budget. Whatever reimbursement 
system is used, if one wants to investigate cost- 
effectiveness of procedures from a hospital per- 
spective, the actual cost is the preferred value to 
analyse. 11 
The high cost of bypass surgery for critical ischae- 
mia is justified by the understanding that this option 
results in the highest limb salvage rate while overall 
costs are lower than for primary amputation. 19"2° 
Endovascular procedures are mostly applicable in 
patients with claudication as the results in critical 
ischaemia re poorY The significance of cost aspects 
of management decisions in intermittent claudication 
is less clear-cut. The extent of discomfort and whether 
a patient's lifestyle is being restricted is difficult to 
estimate, let alone the economic impact of this 
symptom. If claudication does not lead to loss of work, 
or interferes with basic daily activities and independ- 
ent living the decision for active intervention with its 
associated risks should not be taken lightly. Cost 
aspects of endovascular and open surgery have been 
22 23 the subject of several studies. ' However, in most of 
these studies comparing treatment costs between 
groups BA was only used in patients with "suitable 
lesions", while surgery was performed in cases with 
more extensive disease and with a presumably higher 
incidence of risk factors for complications and recur- 
rent disease. In this study we have attempted to 
compare patients that were matched as well as 
possible in a non-randomised study. In addition to a 
contemporary group undergoing recanalisation and 
balloon angioplast3~ a historic series of patients with 
endarterectomy of similar arterial occlusions was 
closely examined with regard to cost and duration of 
primary and tertiary patency. 
In cost-effectiveness analysis, different echnologies 
are compared with regard to their costs and their 
effects, for instance gained life years. In cost-utility 
analysis, gained life years are combined with the 
quality of these years and expressed in quality 
adjusted life years (QUALYs). These cost assessment 
techniques are currently used throughout medicine 
including vascular studies. 24 We have performed a 
cost-effectiveness analysis with the treatment effects 
represented by gained patent artery months and the 
results expressed as cost-to-patency ratios. To our 
knowledge, a cost-to-patency ratio has not been 
reported before. This ratio is based on objective 
variables and appears a useful parameter that can 
easily be used for the comparison of patient groups. In 
addition, a cost-to-patency ratio appears applicable in 
a retrospective study, provided that the patient follow- 
up was adequate. In this study the patency figures 
closely paralleled the maintenance of the clinical/ 
haemodynamic improvement; however, we preferred 
to use the more objective anatomic patency for cost- 
effectiveness a sessment. 
As expected the costs for initial treatment in the EA 
group exceeded the costs in the BA group con- 
siderably (Fig. 4). This was due to the higher costs of 
the use of the operating room, anaesthesia nd 
prosthetic material for patch plasty in a large propor- 
tion of the patients, the stay in the ICU and longer 
admission times. Secondary procedures were per- 
formed at a mean of 0.3 per patient and the additional 
expenditure of redos improved the 3-year patency rate 
by 7% in EA as opposed to 30% in BA patients at 3 
years. Costs associated with foUow-up and reinterven- 
tions, were 20% of the total costs in EA and 48% in the 
BA groups. If redo procedures were involved, a new 
work-up, the extra admission time, and the procedure 
itself added to the total costs in this group. If a 
femoropopliteal bypass was indicated, as in two EA 
patients and 10 BA patients, the use of prosthetic 
materials increased the costs substantially. The policy 
in our department was to use PTFE prostheses as a 
bypass if the distal anastomosis was above-the-knee, 
which was the type of bypass most often indicated in 
the patients with redo procedures in this study. 
Although the difference in total cost between EA and 
BA patients is less than in the primary costs, the mean 
total costs of EA patients still exceeded those of BA 
patients by approximately 20% (Fig. 4). We found the 
cost per tertiary patency month particularly impor- 
tant. This ratio included the patency gained by 
successful redo procedures. It appeared that this cost- 
to-patency ratio in EA was not only comparable to the 
ratio in the overall BA group but also to the category 
of BA with initial success. This indicates that the 
durability of patency combined with a low incidence 
of redo procedures after EA resulted in comparable 
cost-effectiveness to BA. These findings are in contrast 
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to most of the literature comparing surgery and 
endovascular p ocedures, in which a cost-advantage 
of catheter techniques i suggested. 1°'22"23 We feel that 
our findings disclose serious flaws within these 
previous studies with regard to incomparability of
clinical variables and lesion characteristics in the 
treatment groups, while they do not take into con- 
sideration the influence of secondary procedures and 
the duration of patency. Our conclusions were main- 
tained when the data were subjected to a sensitivity 
analysis by assuming a different duration of admis- 
sion and procedural costs. In general, cost-effective- 
ness studies are based on factors that are likely to vary 
between different hospitals and countries and a 
sensitivity analysis can be used to determine the 
robustness of the results and to make them broader 
applicable. 
In this analysis some adjustments were made. To 
provide a more current reflection of costs for the 
different patient groups all expenses and labour 
calculation were based on a price level of 1992. 
Because the duration of follow-up was a crucial factor 
for the determination of the cost-effectiveness ratio, 
the follow-up period of patients with patent EAs for 
longer than 72 months were assigned in a random 
fashion to either a 2 or a 3 year follow-up period. This 
adjustment produced a duration of follow-up profile 
and mean duration of follow-up that both were 
comparable for the two treatment groups. 
Admission costs on a surgical ward, i.e. hotel cost 
and food as well as costs for pharmac)~ intravenous 
infusions and laboratory tests were responsible for 
41% of the total costs in EA patients, compared to 19% 
in the BA group. In a multivariate analysis treatment 
by EA was an independent determining factor of the 
LOS together with the presence of associated proce- 
dures, complications or failure to recanalise the 
occlusion. At present, with a more cost-aware attitude 
than in the early 1980s, these long admission times 
may be reduced sharply. The high primary patency 
rate of 87% after 3 years of surgery justify the high 
initial treatment costs, in particular if compared to a 
patency of only 44% following recanalisation a d BA. 
From the sensitivity analysis it appeared that a 
reduction of the LOS of 30% in EA patients resulted in 
a more favourable conomic picture compared to the 
observed costs of BA treatment (NF1280 per month vs.  
NF1 287 per month, Table 4). 
Are endarterectomy and balloon angioplasty as 
methods to treat superficial femoral artery occlusions 
up to a length of 15 cm interchangeable, simply 
because they have comparable cost-effectiveness? The 
answer can not be a simple yes or no as so many 
clinical factors are involved. What we can learn of this 
study is that it is worthwhile to look for alternatives 
such as new treatments that combine the high primary 
patency of open surgery with the low initial costs of 
endovascular procedures. Limited open procedures 
combining recanalisation, transluminal grafting or 
stent-grafting and remote ndarterectomy arethe new 
techniques that are currently being explored. 25" 26 An 
unbiased assessment of the benefits of these new 
techniques will be essential as the lessons of the past 
have learned that the qualifications "new" and "endo- 
vascular" may easy lead to their indiscriminate use 
and unvalidated claims of favourable cost- 
effectiveness. 
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